(310) 476-7002
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 3, 2016, MMRGlobal, Inc. (the "Company") held its 2016 Annual Meeting of Stockholders (the "Annual Meeting"). The Company's stockholders were asked to
consider and vote upon the following three proposals:
Proposal 1. To elect two (2) Class I directors to serve for a term of three (3) years, with such term expiring upon the 2019 Annual Meeting of Stockholders or until their respective
successors are duly elected and qualified.
Proposal 2. To ratify the appointment of Rose Snyder & Jacobs as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
Proposal 3. To approve our Executive Compensation.
The following sets forth detailed information regarding the voting results at the Annual Meeting:
Proposal No. 1:
|
Director:
|
For:
|
Withheld:
|
Not Voted:
|
|
Titus Day
|
126,780,957
|
1,016,409
|
28,322,737
|
|
Scott C. Kline
|
126,780,957
|
1,016,409
|
28,322,737
|
Proposal No. 2:
|
Votes For:
|
Votes Against:
|
Votes Abstaining:
|
|
156,120,103
|
0
|
0
|
Proposal No. 3:
|
Votes For:
|
Votes Against:
|
Votes Abstaining:
|
|
126,256,343
|
1,241,023
|
300,000
|
Item 7.01 Regulation FD Disclosure.
The following information is being "furnished" in accordance with General Instruction B.2. of Form 8-K and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific
reference in such filing.
In connection with the "Q&A" period of the Company's 2016 Annual Meeting, the Company's CEO and Secretary discussed certain of the Company's business
prospects, including the following:
a. Potential Zika Virus test distribution opportunity. Certain of the Company's officers and
directors are negotiating the terms of a possible exclusive license in a South American territory, and other first rights of refusal, of a newly created rapid result Zika
virus in-home test created by a Southern California company (the "Manufacturer"). The potential opportunity was introduced through
relationships established by Dr. Ivor Royston, a member of the Company's Board of Directors, our CEO, Robert Lorsch, and our Secretary, Scott Kline. The Company's
officers are not representing the Company with respect to the acquisition of the license, however are doing it based in part on assigning certain distribution rights
to the Company if the license is obtained. The potential transaction is still in the due diligence phase, specifically pertaining to the Manufacturer's relationship with the FDA.
Notwithstanding the due diligence phase, a preliminary deal point memorandum has been signed by a California LLC that is controlled by Dr. Royston, provided however no
definitive agreements have been executed by any of the parties or with the Company. No assurances can be given that any agreements will be
reached or that if such agreements are reached, that the Company would be able successful in taking advantage of such distribution rights.
b. License/Sale of Company Assets. The Company has received a significant expression
of interest from a major Nutritional Products organization with regard to licensing or purchasing all or a portion of the Company's Biotech Samples and other patient
information from the Favrille FavId trials. The Company believes that such assets have increasing significant value. Notwithstanding this, no
assurances can be given that any agreements will be reached regarding the license or sale of these assets on terms favorable to the Company, if at all.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
MMRGLOBAL, INC.
|
|
August 5, 2016
|
|
By:
/s/ Robert H. Lorsch
Robert H. Lorsch
Chief Executive Officer
|